A Fairytale of New York (NYSE and the Nasdaq)
Henry Jennings
December 21, 2023
It has been a year of extraordinary moves in things
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
It has been a year of extraordinary moves in things
The CSL Limited (ASX:CSL) share price has risen 0.8% since
BHP Group’s Chief Financial Officer David Lamont sat down with
The Resmed CDI (ASX:RMD) share price is down around 14.9%
The CSL Limited (ASX:CSL) share price has decreased 1.1% since
The mood was distinctly positive on the trading screens, with
Australia’s share market pushed higher on Wednesday, as the big
The Resmed CDI (ASX:RMD) share price has decreased 16.4% since
The benchmark S&P/ASX 200 (INDEXASX: XJO) index added 36.3 points,
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
